Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including Wegovy and Zepbound are expected to be easier to access and afford. And new ...

GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published in JAMA in January 2025 — which looked ...

The FDA just approved the first pill version of a blockbuster GLP-1 drug for weight loss, a move that could significantly widen access to the treatment, though the full costs aren’t clear. The ...

The FDA has approved a pill form of the popular injectable obesity drug Wegovy. People on the highest dose dropped about 14 percent of their starting weight after 64 weeks, with a high number of ...

The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk's weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...

Anjali Sachan explains, “One kilogram of fat equals roughly 7,700 calories. This comes from actual stored body fat, not water weight, bloating, or glycogen. Real fat loss takes time because fat is ...

As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels' indications, including for people with a normal body mass index and no ...

In case you've faced some hurdles solving the clue, 1 or 2 on the Kinsey scale, perhaps, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy ...

Linda McMahon, 57, chuckled recalling her Thanksgiving with the "Mounjaro crew" — herself and friends who are taking GLP-1 medications. "If you saw our plates you would have laughed," she said.

Ascletis Pharma has posted 7.7% weight loss for the highest dose of its own entrant in the highly contested oral GLP-1 race. The Chinese biotech evaluated three different once-daily doses of its oral ...

Ash-har Quraishi is a consumer correspondent based in Chicago. He is an Emmy Award-winning journalist with more than 25 years of local, national, international and investigative reporting experience.